Subject(s)
Bone Neoplasms , Calcinosis , Lung Neoplasms , Osteosarcoma , Tomography, X-Ray Computed , Humans , Osteosarcoma/diagnostic imaging , Osteosarcoma/secondary , Osteosarcoma/pathology , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Lung Neoplasms/pathology , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/secondary , Tomography, X-Ray Computed/methods , Calcinosis/diagnostic imaging , Male , FemaleABSTRACT
BACKGROUND: Telangiectatic osteosarcoma is rare and it rarely affects flat bones, especially the bones of the pelvis. It is uncommon for telangiectatic osteosarcoma to be considered as a differential diagnosis when assessing a large intrabdominal mass. CASE REPORT: We present our case of a 33-year-old African female who presented with a sizeable telangiectatic osteosarcoma of the left iliac bone. She reported a 3-year duration of a painless, slow-growing mass arising from the left flank. At examination, a large bony hard mass extending from the left ilium to the umbilicus was noted, almost mimicking an intra-abdominal pregnancy. All laboratory tests were within normal limits and an unconventional surgical approach was used for a one-stage excision of the tumor without complications. The definitive histopathological diagnosis postexcision was that of a telangiectatic osteosarcoma only on the second review of the histological specimen. CONCLUSIONS: Pelvic telangiectatic osteosarcoma is rare, and the ilium is the commonly affected pelvic bone. These tumors can be sizeable at presentation with intra-abdominal or pelvic extension with a high chance of misdiagnosis. Fortunately surrounding soft tissue involvement seems to be a rare and late finding when present.
Subject(s)
Bone Neoplasms , Ilium , Osteosarcoma , Telangiectasis , Humans , Female , Osteosarcoma/pathology , Osteosarcoma/diagnostic imaging , Osteosarcoma/surgery , Osteosarcoma/diagnosis , Adult , Telangiectasis/pathology , Telangiectasis/diagnosis , Bone Neoplasms/pathology , Bone Neoplasms/surgery , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/diagnosis , Ilium/pathology , Ilium/diagnostic imaging , Diagnosis, Differential , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: Extraskeletal osteosarcoma is an extremely rare malignancy that accounts for 1% of soft tissue sarcoma and 4.3% of all osteosarcoma. Extraskeletal osteosarcoma can develop in a patient between the ages of 48 and 60 years. The incidence of extraskeletal osteosarcoma is slightly higher in male patients than in females. CASE PRESENTATION: A 50-year-old Caucasian male patient presented with a 6-month history of intermittent lower-left back pain that limits his activity. Prior ultrasonography and abdominal computed tomography scan showed a diagnosis of kidney stone and tumor in the lower-left abdomen. The computed tomography urography with contrast revealed a mass suspected as a left retroperitoneal malignant tumor. Hence, the tumor was resected through laparotomy and the patient continued with histopathological and immunohistochemistry examination with the result of extraskeletal osteosarcoma. CONCLUSION: Extraskeletal osteosarcoma presents diagnostic challenges requiring multimodal examination, including histological and immunohistochemistry analyses. This case underscores the aggressive nature and poor prognosis despite undergoing the current suggested treatment.
Subject(s)
Osteosarcoma , Tomography, X-Ray Computed , Humans , Male , Middle Aged , Osteosarcoma/pathology , Osteosarcoma/diagnosis , Osteosarcoma/diagnostic imaging , Kidney Neoplasms/pathology , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/surgery , Kidney Neoplasms/diagnosis , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/diagnostic imaging , Pancreatic Neoplasms/surgery , Stomach Neoplasms/pathology , Stomach Neoplasms/diagnosis , Stomach Neoplasms/diagnostic imaging , Stomach Neoplasms/surgery , Splenic Neoplasms/pathology , Splenic Neoplasms/surgery , Splenic Neoplasms/diagnosis , Splenic Neoplasms/diagnostic imaging , Retroperitoneal Neoplasms/pathology , Retroperitoneal Neoplasms/diagnostic imaging , Retroperitoneal Neoplasms/diagnosis , Retroperitoneal Neoplasms/surgerySubject(s)
Femoral Neoplasms , Femur , Osteosarcoma , Humans , Osteosarcoma/diagnostic imaging , Osteosarcoma/pathology , Femoral Neoplasms/diagnostic imaging , Femur/diagnostic imaging , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/pathology , Male , Tomography, X-Ray Computed/methods , Magnetic Resonance Imaging/methods , FemaleABSTRACT
BACKGROUND: Osteosarcoma of the jaws is a rare primary malignant tumor of bone. The clinical, radiological and histopathological features of a case associated with cemento-osseous dysplasia is presented. CASE REPORT: A 57-year-old mixed-race female presented with a large, progressive, swelling of the right mandible. Radiographic examination revealed two associated lesions. Partially defined irregular radiopacities were noted in the left mandible, extending from the premolar to the molar region. The lesion had a cotton-wool appearance and resembled a fibro-osseous lesion; i.e. cemento-osseous dysplasia. A second large, expansive and irregular, radiopaque lesion was noted on the right angle of the mandible, extending beyond the inferior cortex of the mandible. The internal structure was heterogeneous and resembled irregular bone formation. The classic "sunburst" appearance of radiating bony spicules can be seen in the posterior-anterior view and the CBCT 3D reconstruction, indicating the outgrowth of the tumor matrix. Histopathological exam confirmed a final diagnosis of osteosarcoma closely associated with cemento-osseous dysplasia. The patient underwent a fludeoxyglucose-18 (FDG) positron emission tomography (PET) scan which indicated metastasis in the left lung and increased uptake in the right mandible. Chemotherapy was initially administered with a plan to resect the tumor, however, the patient demised as a result of medical complications. CONCLUSION: The question in the literature remains whether these two entities are coincidentally found or arise from each other. Nevertheless, it is important for clinicians to closely monitor patients with cemento-osseous dysplasia and biopsy any suspicious lesions that may develop into osteosarcoma.
Subject(s)
Cementoma , Mandibular Neoplasms , Osteosarcoma , Humans , Female , Osteosarcoma/diagnostic imaging , Middle Aged , Mandibular Neoplasms/diagnostic imaging , Cementoma/diagnostic imaging , Radiopharmaceuticals , Fluorodeoxyglucose F18 , Cone-Beam Computed Tomography , Diagnosis, DifferentialABSTRACT
BACKGROUND: Osteosarcoma is the most common primary malignant bone tumour in children and adolescents. Lungs are the most frequent and often the only site of metastatic disease. The presence of pulmonary metastases is a significant unfavourable prognostic factor. Thoracotomy is strongly recommended in these patients, while computed tomography (CT) remains the gold imaging standard. The purpose of our study was to create tools for the CT-based qualification for thoracotomy in osteosarcoma patients in order to reduce the rate of useless thoracotomies. METHODS: Sixty-four osteosarcoma paediatric patients suspected of lung metastases on CT and their first-time thoracotomies (n = 100) were included in this retrospective analysis. All CT scans were analysed using a compartmental evaluation method based on the number and size of nodules. Calcification and location of lung lesions were also analysed. Inter-observer reliability between two experienced radiologists was assessed. The CT findings were then correlated with the histopathological results of thoracotomies. Various multivariate predictive models (logistic regression, classification tree and random forest) were built and predictors of lung metastases were identified. RESULTS: All applied models proved that calcified nodules on the preoperative CT scan best predict the presence of pulmonary metastases. The rating of the operated lung on the preoperative CT scan, dependent on the number and size of nodules, and the total number of nodules on this scan were also found to be important predictors. All three models achieved a relatively high sensitivity (72-92%), positive predictive value (81-90%) and accuracy (74-79%). The positive predictive value of each model was higher than of the qualification for thoracotomy performed at the time of treatment. Inter-observer reliability was at least substantial for qualitative variables and excellent for quantitative variables. CONCLUSIONS: The multivariate models built and tested in our study may be useful in the qualification of osteosarcoma patients for metastasectomy through thoracotomy and may contribute to reducing the rate of unnecessary invasive procedures in the future.
Subject(s)
Bone Neoplasms , Lung Neoplasms , Osteosarcoma , Thoracotomy , Tomography, X-Ray Computed , Humans , Osteosarcoma/diagnostic imaging , Osteosarcoma/surgery , Osteosarcoma/secondary , Osteosarcoma/pathology , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/surgery , Lung Neoplasms/secondary , Lung Neoplasms/pathology , Adolescent , Child , Retrospective Studies , Male , Female , Bone Neoplasms/secondary , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/surgeryABSTRACT
BACKGROUND: New immunotherapies activate tumor-associated macrophages (TAMs) in the osteosarcoma microenvironment. Iron oxide nanoparticles (IONPs) are phagocytosed by TAMs and, therefore, enable TAM detection on T2*- and T2-weighted magnetic resonance images. We assessed the repeatability and reproducibility of T2*- and T2-mapping of osteosarcomas in a mouse model. METHODS: Fifteen BALB/c mice bearing-murine osteosarcomas underwent magnetic resonance imaging (MRI) on 3-T and 7-T scanners before and after intravenous IONP infusion, using T2*-weighted multi-gradient-echo, T2-weighted fast spin-echo, and T2-weighted multi-echo sequences. Each sequence was repeated twice. Tumor T2 and T2* relaxation times were measured twice by two independent investigators. Repeatability and reproducibility of measurements were assessed. RESULTS: We found excellent agreement between duplicate acquisitions for both T2* and T2 measurements at either magnetic field strength, by the same individual (repeatability), and between individuals (reproducibility). The repeatability concordance correlation coefficient (CCC) for T2* values were 0.99 (coefficients of variation (CoV) 4.43%) for reader 1 and 0.98 (CoV 5.82%) for reader 2. The reproducibility of T2* values between the two readers was 0.99 (CoV 3.32%) for the first acquisitions and 0.99 (CoV 6.30%) for the second acquisitions. Regarding T2 values, the repeatability of CCC was similar for both readers, 0.98 (CoV 3.64% for reader 1 and 4.45% for reader 2). The CCC of the reproducibility of T2 was 0.99 (CoV 3.1%) for the first acquisition and 0.98 (CoV 4.38%) for the second acquisition. CONCLUSIONS: Our results demonstrated high repeatability and reproducibility of quantitative T2* and T2 mapping for monitoring the presence of TAMs in osteosarcomas. RELEVANCE STATEMENT: T2* and T2 measurements of osteosarcomas on IONP-enhanced MRI could allow identifying patients who may benefit from TAM-modulating immunotherapies and for monitoring treatment response. The technique described here could be also applied across a wide range of other solid tumors. KEY POINTS: ⢠Optimal integration of TAM-modulating immunotherapies with conventional chemotherapy remains poorly elucidated. ⢠We found high repeatability of T2* and T2 measurements of osteosarcomas in a mouse model, both with and without IONPs contrast, at 3-T and 7-T MRI field strengths. ⢠T2 and T2* mapping may be used to determine response to macrophage-modulating cancer immunotherapies.
Subject(s)
Bone Neoplasms , Disease Models, Animal , Magnetic Resonance Imaging , Mice, Inbred BALB C , Osteosarcoma , Animals , Osteosarcoma/diagnostic imaging , Mice , Magnetic Resonance Imaging/methods , Reproducibility of Results , Bone Neoplasms/diagnostic imaging , FemaleABSTRACT
Myositis ossificans, a benign tumor composed of spindle cells and osteoblasts, can clinically and radiologically mimic osteosarcoma. While recognition and accurate diagnosis of myositis ossificans can be a challenge, this is critical as it may allow a conservative surgical approach to maximize functional outcomes. Herein, we present a patient with surface myositis ossificans confirmed genetically by the presence of COL1A1::USP6 gene fusion, along with a literature review. Due to the enhanced visualization of the bone matrix, computed tomography (CT) imaging may be a superior imaging modality to magnetic resonance (MR) imaging. Staged biopsies with samples obtained from the periphery and center of the lesions may allow pathologists to discern the zonal distribution histologically. Furthermore, immunohistochemistry fluorescence in situ hybridization and molecular testing can aid in the distinction of myositis ossificans from mimics. Because of their resemblance to other bone tumors, these cases of myositis ossificans highlight the importance of a multidisciplinary approach integrating clinical, radiologic, and pathologic analysis and involving serial imaging, sampling, and judicious use of ancillary immunohistochemical and molecular testing.
Subject(s)
Myositis Ossificans , Osteosarcoma , Humans , Bone Neoplasms/pathology , Bone Neoplasms/diagnosis , Bone Neoplasms/diagnostic imaging , Collagen Type I/genetics , Collagen Type I/analysis , Collagen Type I, alpha 1 Chain , Diagnosis, Differential , Immunohistochemistry , In Situ Hybridization, Fluorescence , Magnetic Resonance Imaging , Myositis Ossificans/diagnosis , Myositis Ossificans/pathology , Myositis Ossificans/diagnostic imaging , Myositis Ossificans/genetics , Osteosarcoma/diagnosis , Osteosarcoma/pathology , Osteosarcoma/diagnostic imaging , Tomography, X-Ray Computed , Ubiquitin ThiolesteraseABSTRACT
BACKGROUND: Osteosarcoma (OS) is a prevalent primary bone cancer affecting both humans and canines. This study describes initial insights into the interaction of the human monoclonal antibody IF3 to an insulin-like growth factor 2 receptor (IGF2R) radiolabeled with either alpha-emitting Actinium-225 (225Ac) or beta-emitting Lutetium-177 (177Lu) radionuclides with the OS cells and tumor microenvironment (TME) in experimental human and canine OS. BASIC PROCEDURES: SCID mice bearing canine Gracie or human OS-33 OS tumors were treated with 177Lu- or 225Ac-labeled IF3 antibody, sacrificed at 24, 72 or 168 h post-treatment and their tumors were analyzed by immunohistochemistry (IHC) for the presence of OS cells, various elements of TME as well as for the double DNA strand breaks with γH2AX and caspase 3 assays. MAIN FINDINGS: IHC revealed a reduction in IGF2R-positive OS cells and OS stem cell populations post therapy with 225Ac- and 177Lu-labeled IF3 antibody. Notably, radiolabeled IF3 antibody effectively diminished pro-tumorigenic M2 macrophages, highlighting its therapeutic promise. The study also unveiled varied responses of natural killer (NK) cells and M1 macrophages, shedding light on the intricate TME interplay. Time-dependent increase in γ-H2AX staining in canine Gracie and human OS-33 tumors treated with [177Lu]Lu-IF3 and [225Ac]Ac-IF3 was observed at 24 and 72 h post-RIT. PRINCIPAL CONCLUSIONS: These findings suggest that radiolabeled antibodies offer a hopeful avenue for personalized OS treatment, emphasizing the importance of understanding their impact on the TME and potential synergies with immunotherapy.
Subject(s)
Actinium , Lutetium , Osteosarcoma , Radioisotopes , Tumor Microenvironment , Animals , Dogs , Humans , Osteosarcoma/metabolism , Osteosarcoma/pathology , Osteosarcoma/diagnostic imaging , Mice , Cell Line, Tumor , Antibodies, Monoclonal , Isotope Labeling , Bone Neoplasms/metabolism , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/pathology , Bone Neoplasms/immunologyABSTRACT
CASE: A 79-year-old woman presented with a periprosthetic fracture 8 years after a total knee arthroplasty (TKA). Radiographs demonstrated tibial implant loosening with severe osteolysis. A high-grade osteosarcoma around the prosthesis was diagnosed, and a supracondylar femoral amputation was performed. After 2 years, no complications have occurred. CONCLUSIONS: A malignant tumor around a TKA is extremely rare. Surgeons should remain vigilant with patients who present with rapidly progressive or very aggressive implant loosening with osteolysis. Owing to its complexity and potentially devastating prognosis, treatment should be guided by a specialist multidisciplinary team. Complex limb salvage procedures or amputation is usually required.
Subject(s)
Arthroplasty, Replacement, Knee , Bone Neoplasms , Osteosarcoma , Humans , Female , Osteosarcoma/surgery , Osteosarcoma/diagnostic imaging , Arthroplasty, Replacement, Knee/adverse effects , Aged , Bone Neoplasms/surgery , Bone Neoplasms/diagnostic imaging , Amputation, Surgical , Periprosthetic Fractures/etiology , Periprosthetic Fractures/surgery , Periprosthetic Fractures/diagnostic imaging , Prosthesis FailureABSTRACT
Sarcomatous transformation of fibrous dysplasia is extremely rare. We present the case of a 54-yearold man with multiple rib masses, multiple enlarged lymph nodes throughout the body, and multiple osteolytic lesions on computed tomography( CT). A positron emission tomography( PET) scan showed abnormal enhancement in each. A needle biopsy of the right supraclavicular fossa lymph node revealed sarcoidosis. Considering the possibility of malignancy associated with sarcoidosis, a rib tumor resection and mediastinal lymph node biopsy were performed to confirm the diagnosis of the rib lesion. The pathology results showed that the rib mass was a low-grade central osteosarcoma and the mediastinal lymph node was sarcoidosis. The distribution of the lesions was consistent with osteosarcoma secondary to multiple fibrous bone dysplasia. As the osteosarcoma was low grade, the patient was followed up. Three years after surgery, there was no increase in residual disease.
Subject(s)
Bone Neoplasms , Osteosarcoma , Ribs , Humans , Male , Ribs/diagnostic imaging , Ribs/surgery , Osteosarcoma/diagnostic imaging , Osteosarcoma/surgery , Osteosarcoma/complications , Middle Aged , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/surgery , Bone Neoplasms/complications , Tomography, X-Ray Computed , Fibrous Dysplasia of Bone/diagnostic imaging , Fibrous Dysplasia of Bone/complications , Fibrous Dysplasia of Bone/surgery , Fibrous Dysplasia, Polyostotic/diagnostic imaging , Fibrous Dysplasia, Polyostotic/complications , Fibrous Dysplasia, Polyostotic/surgeryABSTRACT
INTRODUCTION: Osteosarcoma (OS) and Ewing sarcoma (ES) represent the pediatric population's most common malignant bone tumors. 18-Fluorodeoxyglucose positron emission tomography has been shown to be effective in both the diagnostic and staging phases of cancer treatment. In recent years, some studies have also explored the possibility that FDG-PET could have a prognostic role.
Subject(s)
Bone Neoplasms , Fluorodeoxyglucose F18 , Osteosarcoma , Positron-Emission Tomography , Radiopharmaceuticals , Sarcoma, Ewing , Humans , Sarcoma, Ewing/diagnostic imaging , Sarcoma, Ewing/pathology , Sarcoma, Ewing/drug therapy , Osteosarcoma/diagnostic imaging , Osteosarcoma/pathology , Osteosarcoma/drug therapy , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/drug therapy , Bone Neoplasms/pathology , Necrosis , PrognosisABSTRACT
Serial fluorine 18 fluorodeoxyglucose (18F-FDG) positron emission tomography-CT (PET/CT) is commonly used in human oncology to prognosticate and evaluate for therapeutic effectiveness. In this pilot study, dogs with naturally occurring appendicular osteosarcoma were evaluated with serial 18F-FDG PET/CT in an attempt to assess for response to therapy, prognostic factors, and appropriateness of imaging intervals. Fourteen dogs were enrolled in the trial. All dogs had the initial 18F-FDG PET/CT (PET1), with nine dogs having their end-of-therapy 18F-FDG PET/CT (EoT PET) 3 months after stereotactic body radiation therapy (SBRT) to the primary tumor. The median percent change from the PET1 to the EoT PET for the standard uptake value maximum (SUVmax%) was -58% (range: -17 to -88%), metabolic tumor volume (MTV%) was -99.8% (range: -65 to -100%), and total lesion glycolysis (TLG%) was -99.8% (range: -75 to -100%), all of which were significant (P < .05, <.05, and <.05, respectively). On evaluation, it was found that volumes of GTV and CTV were significant for survival (P < .05 and <.05), MTV1, TLG1, and SUVmax on the EoT PET (SUVmaxEoT) were predictive of metastasis (P < .05), and the SUVmax% was significantly correlated to the time to first event (P < .05). Based on this data, serial 18F-FDG PET/CT performed 3 months after SBRT can show a significant reduction in avidity, and the quantitative data collected may help predict metastatic disease in canine appendicular osteosarcoma.
Subject(s)
Carboplatin , Dog Diseases , Fluorodeoxyglucose F18 , Osteosarcoma , Positron Emission Tomography Computed Tomography , Radiopharmaceuticals , Radiosurgery , Animals , Dogs , Osteosarcoma/veterinary , Osteosarcoma/diagnostic imaging , Pilot Projects , Dog Diseases/diagnostic imaging , Dog Diseases/radiotherapy , Dog Diseases/mortality , Positron Emission Tomography Computed Tomography/veterinary , Female , Male , Prospective Studies , Radiopharmaceuticals/therapeutic use , Radiosurgery/veterinary , Carboplatin/therapeutic use , Appendiceal Neoplasms/veterinary , Appendiceal Neoplasms/diagnostic imaging , Appendiceal Neoplasms/therapy , Antineoplastic Agents/therapeutic use , Treatment Outcome , Prognosis , Bone Neoplasms/veterinary , Bone Neoplasms/radiotherapy , Bone Neoplasms/diagnostic imagingABSTRACT
BACKGROUND: As the lethal bone tumor, osteosarcoma often frequently occurs in children and adolescents with locally destructive and high metastasis. Distinctive kinds of nanoplatform with high therapeutical effect and precise diagnosis for osteosarcoma are urgently required. Multimodal optical imaging and programmed treatment, including synergistic photothermal-chemodynamic therapy (PTT-CDT) elicits immunogenetic cell death (ICD) is a promising strategy that possesses high bio-imaging sensitivity for accurate osteosarcoma delineating as well as appreciable therapeutic efficacy with ignorable side-effects. METHODS AND RESULTS: In this study, mesoporous Cu and Ce based oxide nanoplatform with Arg-Gly-Asp (RGD) anchoring is designed and successfully constructed. After loading with indocyanine green, this nanoplatform can be utilized for precisely targeting and efficaciously ablating against osteosarcoma via PTT boosted CDT and the closely following ICD stimulation both in vitro and in vivo. Besides, it provides off-peak fluorescence bio-imaging in the second window of near-infrared region (NIR II, 1000-1700 nm) and Magnetic resonance signal, serves as the dual-mode contrast agents for osteosarcoma tissue discrimination. CONCLUSION: Tumor targeted Cu&Ce based mesoporous nanoplatform permits efficient osteosarcoma suppression and dual-mode bio-imaging that opens new possibility for effectively diagnosing and inhibiting the clinical malignant osteosarcoma.
Subject(s)
Bone Neoplasms , Nanoparticles , Neoplasms , Osteosarcoma , Child , Humans , Adolescent , Magnetic Resonance Imaging/methods , Magnetic Resonance Spectroscopy , Osteosarcoma/diagnostic imaging , Osteosarcoma/therapy , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/drug therapy , Immunotherapy , Cell Line, Tumor , PhototherapyABSTRACT
Automated Osteosarcoma Segmentation in Multi-modality MRI (AOSMM) holds clinical significance for effective tumor evaluation and treatment planning. However, the precision of AOSMM is challenged by the diverse characteristics of multi-modality MRI and the inherent heterogeneity and boundary ambiguity of osteosarcoma. While numerous methods have made significant strides in automated osteosarcoma segmentation, they primarily focused on the use of a single MRI modality and overlooked the potential benefits of integrating complementary information from other MRI modalities. Furthermore, they did not adequately model the long-range dependencies of complex tumor features, which may lead to insufficiently discriminative feature representations. To this end, we propose a decoupled semantic and boundary learning network (DECIDE) to achieve precise AOSMM with three functional modules. The Multi-modality Feature Fusion and Recalibration (MFR) module adaptively fuses and recalibrates multi-modality features by exploiting their channel-wise dependencies to compute low-rank attention weights for effectively aggregating useful information from different MRI modalities, which promotes complementary learning between multi-modality MRI and enables a more comprehensive tumor characterization. The Lesion Attention Enhancement (LAE) module employs spatial and channel attention mechanisms to capture global contextual dependencies over local features, significantly enhancing the discriminability and representational capacity of intricate tumor features. The Boundary Context Aggregation (BCA) module further enhances semantic representations by utilizing boundary information for effective context aggregation while also ensuring intra-class consistency in cases of boundary ambiguity. Substantial experiments demonstrate that DECIDE achieves exceptional performance in osteosarcoma segmentation, surpassing state-of-the-art methods in terms of accuracy and stability.
Subject(s)
Bone Neoplasms , Magnetic Resonance Imaging , Osteosarcoma , Osteosarcoma/diagnostic imaging , Humans , Magnetic Resonance Imaging/methods , Bone Neoplasms/diagnostic imaging , Semantics , Image Interpretation, Computer-Assisted/methods , Multimodal Imaging/methodsABSTRACT
OBJECTIVE: To report the incidence of indeterminate pulmonary nodules (IPN) and the rate of progression of IPNs to metastasis in patients with primary bone cancers. We also aimed to evaluate clinical or radiological parameters that may identify IPNs more likely to progress to metastatic disease and their effect on overall or event-free survival in patients with primary bone sarcoma. METHODS: A systematic search of the electronic databases Medline, Embase, and Cochrane Library was undertaken for eligible articles on IPNs in patients with primary bone sarcomas, published in the English language from inception of the databases to 2023. The Newcastle-Ottawa Quality Assessment Form for Cohort Studies was utilized to evaluate risk of bias in included studies. RESULTS: Six studies, involving 1667 patients, were included in this systematic review. Pooled quantitative analysis found the rate of incidence of IPN to be 18.1% (302 out of 1667) and the rate of progression to metastasis to be 45.0% (136 out of 302). Nodule size (more than 5 mm diameter), number (more than or equal to 4), distribution (bilaterally distributed), incomplete calcification, and lobulated margins were associated with an increased likelihood of IPNs progressing to metastasis, however, their impact on overall or event-free survival remains unclear. CONCLUSION: The risk of IPNs progressing to metastasis in patients with primary bone sarcoma is non-negligible. Large IPNs have a high risk to be an actual metastasis. We suggest that IPNs in these patients be followed up for a minimum of 2 years with CT imaging at 3, 6, and 12 month intervals, particularly for nodules measuring >5 mm in average diameter. ADVANCES IN KNOWLEDGE: This is the first systematic review on IPNs in patients with primary bone sarcomas only and proposes viable management strategies for such patients.
Subject(s)
Bone Neoplasms , Lung Neoplasms , Multiple Pulmonary Nodules , Humans , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/secondary , Multiple Pulmonary Nodules/diagnostic imaging , Multiple Pulmonary Nodules/pathology , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Osteosarcoma/diagnostic imaging , Osteosarcoma/pathology , Disease Progression , Tomography, X-Ray Computed/methods , Incidence , Clinical RelevanceABSTRACT
OBJECTIVES: Histological tumour necrosis is the current indicator for the response of osteosarcoma after neoadjuvant chemotherapy. Chemoresistant tumours require close monitoring and adjustment of treatment. Characteristics of tumours on baseline MRI may be able to predict response to chemotherapy. The aim is to identify which baseline MRI findings can help predict chemoresistant osteosarcoma. METHODS: Baseline MRI before giving neoadjuvant chemotherapy of 95 patients during 2008-2021 was reviewed by 2 musculoskeletal radiologists. Histological necrosis from surgical specimens was the reference standard. MRIs were reviewed for tumour characteristics (tumour volume, maximum axial diameter, central necrosis, haemorrhage, fluid-fluid level), peritumoural bone and soft tissue oedema, and other parameters including intra-articular extension, epiphyseal involvement, neurovascular involvement, pathologic fracture, and skip metastasis. The cut-off thresholds were generated by receiver operating characteristic curves which then tested for diagnostic accuracy. RESULTS: Two-third of patients were chemoresistance (histological necrosis <90%). Tumour volume >150 mL, maximum axial diameter >7.0 cm, area of necrosis >50%, presence of intra-articular extension, and peritumoural soft tissue oedema >6.5 cm significantly predicted chemoresistance, particularly when found in combination. Tumour volume >150 mL and maximum axial diameter >7.0 cm could be used as an independent predictor (multivariable analysis, P-value = .025, .045). CONCLUSIONS: Findings on baseline MRI could help predicting chemoresistant osteosarcoma with tumour size being the strongest predictor. ADVANCES IN KNOWLEDGE: Osteosarcomas with large size, large cross-sectional diameter, large area of necrosis, presence of intra-articular extension, and extensive peritumoural soft tissue oedema were most likely to have a poor response to neoadjuvant chemotherapy.
Subject(s)
Bone Neoplasms , Osteosarcoma , Humans , Drug Resistance, Neoplasm , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/drug therapy , Osteosarcoma/diagnostic imaging , Osteosarcoma/drug therapy , Osteosarcoma/pathology , Magnetic Resonance Imaging/methods , Necrosis , Edema/diagnostic imaging , Neoadjuvant Therapy/methodsABSTRACT
PURPOSE: To evaluate the performance of CT-based intratumoral, peritumoral and combined radiomics signatures in predicting prognosis in patients with osteosarcoma. METHODS: The data of 202 patients (training cohort:102, testing cohort:100) with osteosarcoma admitted to the two hospitals from August 2008 to February 2022 were retrospectively analyzed. Progression free survival (PFS) and overall survival (OS) were used as the end points. The radiomics features were extracted from CT images, three radiomics signaturesï¼RSintratumoral, RSperitumoral, RScombinedï¼were constructed based on intratumoral, peritumoral and combined radiomics features, respectively, and the radiomics score (Rad-score) were calculated. Kaplan-Meier survival analysis was used to evaluate the relationship between the Rad-score with PFS and OS, the Harrell's concordance index (C-index) was used to evaluate the predictive performance of the radiomics signatures. RESULTS: Finally, 8, 6, and 21 features were selected for the establishment of RSintratumoral, RSperitumoral, and RScombined, respectively. Kaplan-Meier survival analysis confirmed that the Rad-scores of the three RSs were significantly correlated with the PFS and OS of patients with osteosarcoma. Among the three radiomics signatures, RScombined had better predictive performance, the C-index of PSF prediction was 0.833 in the training cohort and 0.814 in the testing cohort, the C-index of OS prediction was 0.796 in the training cohort and 0.764 in the testing cohort. CONCLUSIONS: CT-based intratumoral, peritumoral and combined radiomics signatures can predict the prognosis of patients with osteosarcoma, which may assist in individualized treatment and improving the prognosis of osteosarcoma patients.
Subject(s)
Bone Neoplasms , Osteosarcoma , Humans , Radiomics , Retrospective Studies , Prognosis , Osteosarcoma/diagnostic imaging , Bone Neoplasms/diagnostic imaging , Tomography, X-Ray ComputedABSTRACT
Primary bone tumors in children and adolescents, while rare, pose significant challenges in diagnosis and management. Children treated for Ewing sarcoma and osteosarcoma are offered a 5-year follow-up program after end of treatment, including radiological surveillance of primary location of tumor and the lungs. There is no consensus regarding how often and how the children should be followed with radiological imaging. This retrospective descriptive study of 69 patients (34 with Ewing sarcoma and 35 with osteosarcoma) investigated the consequences of abnormal findings in 1279 follow-up images. Nine relapses were detected, 4 in the Ewing group (3 local and 1 pulmonary) and 5 in the osteosarcoma group (1 local and 4 pulmonary). Of these, only two patients exhibited symptomatic relapses, with the remainder identified through imaging. The positive predictive value for relapse detection was 0.44 in the Ewing group, and 0.5 in the osteosarcoma group. In the Ewing sarcoma patient image follow-up program, the probability of anomaly detection was 12% (95% CI, 10-15). For osteosarcoma patients, the likelihood was 6% (95% CI, 4-8). Our data indicates that abnormal findings on follow-up images rarely represents relapse of tumor. As the surveillance protocol differs between the patient groups, wherein Ewing sarcoma patients primarily are monitored through MRI while osteosarcoma patients are predominantly tracked via X-rays, there is an increased occurrence of incidental findings in the first group. However, it is imperative to interpret imaging data in conjunction with clinical information, avoiding isolated reliance on imaging results when making treatment decisions.